<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727451</url>
  </required_header>
  <id_info>
    <org_study_id>PULSE-PHPF-002</org_study_id>
    <nct_id>NCT03727451</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis</brief_title>
  <official_title>A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellerophon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellerophon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed,
      inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term
      oxygen therapy followed by a long term extension study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2b, open label study to assess the hemodynamic effects of increasing doses of pulsed,
      inhaled nitric oxide (iNO) in subjects with pulmonary hypertension associated with pulmonary
      fibrosis or sarcoidosis on long term oxygen therapy followed by an open label extension study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of mean PAP</measure>
    <time_frame>During a single right heart catheterization procedure</time_frame>
    <description>Mean pulmonary arterial pressure (mPAP) will be measured at iNO 30, 45, 75 and 125 mcg/kg IBW/hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of PCWP</measure>
    <time_frame>During a single right heart catheterization procedure</time_frame>
    <description>Pulmonary capillary wedge pressure (PCWP) will be measured at iNO 30, 45, 75 and 125 mcg/kg IBW/hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of PVR</measure>
    <time_frame>During a single right heart catheterization procedure</time_frame>
    <description>Pulmonary vascular resistance (PVR) will be measured at iNO 30, 45, 75 and 125 mcg/kg IBW/hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of CO</measure>
    <time_frame>During a single right heart catheterization procedure</time_frame>
    <description>Cardiac output (CO) will be measured at iNO 30, 45, 75 and 125 mcg/kg IBW/hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6MWD from Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in 6 minute walk distance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Treatment Emergent Adverse Events</measure>
    <time_frame>During a single right heart catheterization procedure</time_frame>
    <description>Including adverse events related to device deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Rebound</measure>
    <time_frame>During a single right heart catheterization procedure</time_frame>
    <description>Symptoms associated with acute withdrawal of iNO: systemic arterial oxygen desaturation, hypoxemia, bradycardia, tachycardia, systemic hypotension, shortness of breath, near-syncope and syncope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance Saturation Product (DSP)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference in DSP from baseline to Week 16
Difference in DSP from baseline to 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference in dyspnea as measured by UCSD Medical Center Pulmonary Rehabilitation Program Shortness of Breath Questionnaire on a scale from 0 (none at all) to 5 (maximal or unable to do because of breathlessness) from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference in disease specific Quality of Life as measured by St. George's Respiratory Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Averse Events</measure>
    <time_frame>Through study completion; an average of 1 year</time_frame>
    <description>Evaluation of adverse events and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integral Distance Saturation Product (IDSP)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference in IDSP from baseline to Week 16</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Sarcoidosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>PH-Pulmonary Fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
Part 2: Optional open label long term extension at the optimal dose as identified in Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH-Sarcoidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>iNO</intervention_name>
    <description>inhaled nitric oxide</description>
    <arm_group_label>PH-Pulmonary Fibrosis</arm_group_label>
    <arm_group_label>PH-Sarcoidosis</arm_group_label>
    <other_name>iNOPulse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. A primary diagnosis of sarcoidosis as defined by the ATS/ERS/WASOG statement or
             pulmonary fibrosis associated with one of the following conditions:

             2.1 Major IIPs (idiopathic interstitial pneumonias) diagnosed or suspected as one of
             the following:

               -  Idiopathic pulmonary fibrosis

               -  Idiopathic nonspecific interstitial pneumonia

               -  Respiratory bronchiolitis-interstitial lung disease

               -  Desquamative interstitial pneumonia

               -  Cryptogenic organizing pneumonia

               -  Acute interstitial pneumonia

               -  Rare IIPs diagnosis by one of the following:

               -  Idiopathic lymphoid interstitial pneumonia

               -  Idiopathic pleuroparenchymal fibroelastosis

               -  Unclassifiable idiopathic interstitial pneumonias

             2.2 Chronic hypersensitivity pneumonitis

             2.3 Occupational lung disease

             2.4 Connective tissue disease with evidence of significant pulmonary fibrosis

          3. Intermediate or high probability of PH by echocardiogram as assessed by local
             Radiologist/Investigator, or PH as determined by a right heart catheterization (RHC)
             within 5 years prior to Baseline with the following parameters:

               1. Pulmonary vascular resistance (PVR) ˃3 Wood Units (WU) (320 dynes.sec.cm-5)

               2. A left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge
                  pressure (PCWP) ≤ 15 mmHg

               3. A mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg

          4. 6MWD ≥ 100 meters and ≤ 450 meters

          5. WHO Functional Class II-IV

          6. Forced Vital Capacity ≥ 40% predicted within last 6 weeks prior to screening

          7. Females of childbearing potential must have a negative pre-treatment pregnancy test
             (urine).

          8. Age between 18 and 85 years (inclusive)

          9. Clinically stable for at least 4 weeks prior to Baseline in the opinion of the
             Investigator

         10. If on therapy for their parenchymal lung disease and/or sarcoidosis, then the subject
             should be on a stable well-tolerated dose of the medication(s) for at least 4 weeks
             prior to enrollment.

        Exclusion Criteria:

          1. Use of any type of PAH specific therapies

          2. Episodes of disease worsening within 3 months prior to Baseline

          3. Pregnant or breastfeeding females at Screening

          4. Administered L-arginine within 1 month prior to Screening

          5. Any subject who has been enrolled in any previous clinical study with inhaled NO
             administered through pulsed delivery

          6. On more than 6 L/min of oxygen at rest by nasal cannula for less than 4 weeks

          7. Evidence of any connective tissue disease with FVC &gt; 60% in the last 6 months prior to
             screening unless there is evidence of moderate to severe fibrosis on CT scan in the
             opinion of the local radiologist/Investigator

          8. Evidence of clinically significant combined pulmonary fibrosis with emphysema (CPFE)
             if &gt; 15% of lung fields by CT scan show evidence of emphysema in the opinion of the
             local radiologist/Investigator

          9. For subjects with sarcoidosis, clinically significant evidence of pulmonary fibrosis
             on CT scan in the opinion of the local radiologist/Investigator and FVC ≥80% predicted

         10. For subjects continuing on open label therapy, the concurrent use of the INOpulse
             device with a CPAP/BiPAP, or any other positive pressure device

         11. Significant heart failure in the opinion of the Investigator

               1. LVEF&lt;40% or

               2. PCWP on last RHC&gt;15 mmHg (unless concurrent LVEDP &lt;15 mmHg) or

               3. Significant diastolic dysfunction on echocardiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hunter Gillies, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bellerophon Pulse Technologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Parker</last_name>
    <phone>908.574.2661</phone>
    <email>valerie.parker@bellerophon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Edmonds</last_name>
    <phone>908.574.4765</phone>
    <email>amy.edmonds@bellerophon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Simonet</last_name>
      <phone>305-243-3728</phone>
    </contact>
    <investigator>
      <last_name>Roger Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Zigler</last_name>
      <phone>513-584-6252</phone>
    </contact>
    <investigator>
      <last_name>Robert Baughman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dee Fehrlee</last_name>
      <phone>215-707-8043</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim DelGreco</last_name>
      <phone>615-936-2298</phone>
    </contact>
    <investigator>
      <last_name>Jim Loyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Lung Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serina Zorrilla</last_name>
      <phone>703-776-6147</phone>
    </contact>
    <investigator>
      <last_name>Kareem Ahmad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chessa Goss</last_name>
      <phone>206-616-5459</phone>
    </contact>
    <investigator>
      <last_name>Bridget Collins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>Sarcoidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

